Q BioMed Announces Strontium89 Initial Uptake and Momentum in US and EuropeSeveral International Market Authorisations Expected in Q4 Expanding Access to South and Central America and...
Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program COVID-19 clinical trial planned for Q1 2021 supported by Canadian...
Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World Named Patient...
FORT LEE, NJ -- March 19, 2019 -- InvestorsHub NewsWire -- GD Entertainment And Technology (OTC: GDET) (“GDET” or the “Company”) today announced CEO Anil Idnani was...
Four Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements Coral Springs, FL -- July 27, 2016 -- InvestorsHub...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 27765 | 1.0E-6 | CS |
4 | 0 | 0 | 1.0E-6 | 0.0001 | 1.0E-6 | 37415 | 2.513E-5 | CS |
12 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 172510 | 9.021E-5 | CS |
26 | 0 | 0 | 1.0E-6 | 0.0005 | 1.0E-6 | 106346 | 9.291E-5 | CS |
52 | -0.000599 | -99.8333333333 | 0.0006 | 0.0405 | 1.0E-6 | 71731 | 0.00010635 | CS |
156 | -0.496099 | -99.9997984277 | 0.4961 | 0.4961 | 1.0E-6 | 649190 | 0.02642344 | CS |
260 | -2.429999 | -99.9999588477 | 2.43 | 3.75 | 1.0E-6 | 391236 | 0.16767188 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales